On the other hand, MKK3 is either overexpressed or amplified in 3 to 8% of patients in the vast majority of cancers, including thymoma (8%), glioblastoma multiform (7%), and breast invasive carcinoma (6%) (Fig. 4a, Additional file 1: Table S7). Here, MAP2K3 is linked to glioblastoma.